Arkolith/Insider Trading/FUSN/Form 4

Valliant John

Chief Executive Officer, DirectorFusion Pharmaceuticals Inc. (FUSN) · full profile →Form 4 · filed Jun 4, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
12
1 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 4, 2024Disposed to issuer(D)318K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 4, 2024Disposed to issuer(D)320K——0
Jun 4, 2024Disposed to issuer(D)192K——0
Jun 4, 2024Disposed to issuer(D)500K——0
Jun 4, 2024Disposed to issuer(D)407K——0
Jun 4, 2024Disposed to issuer(D)336K——0
Jun 4, 2024Disposed to issuer(D)373K——0
Jun 4, 2024Disposed to issuer(D)207K——0
Jun 4, 2024Disposed to issuer(D)174K——0
Jun 4, 2024Disposed to issuer(D)607K——0
Jun 4, 2024Disposed to issuer(D)270K——0
Jun 4, 2024Disposed to issuer(D)533K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-068905) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML